Jan. 9 (Bloomberg) -- Nanobiotix SA, a French developer of cancer treatments that interact with radiation therapy, is in talks with about 10 potential partners, Chief Executive Officer Laurent Levy said.
Some companies are interested in Nanobiotix’s “whole platform,” while others are focused on one or more products, Levy said in an interview. Nanobiotix, based in Paris, has received some offers already and aims to agree on a partnership in the next six months, he said. Levy declined to comment on which companies are involved in the talks.
Nanobiotix is a spinoff of the State University of New York and funded by venture capital firms including Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone- Alpes, CIC Vizille and Masseran Gestion-CGE, according to its website. Its experimental NanoXray products allow for higher doses of radiation in the tumor without increasing damage to healthy tissue, according to the website.
--Editors: Kristen Hallam, Robert Valpuesta
To contact the reporter on this story: Albertina Torsoli in Paris at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org